Low-molecular-weight heparins, particularly enoxaparin, are widely used for pulmonary embolism prophylaxis in hospitalized patients. Although rare, bleeding has been reported due to these drugs. Because of their excretion from the kidney, the risk of bleeding is higher in the kidney patient population, and these patients should be careful, and dose adjustment should be made. This article reports 2 cases of bleeding due to enoxaparin in 2 different kidney patients who then required transfusion, the literature on this topic has been reviewed.
Cite this article as: Öztürk İ, Şimşir M, Erken E, Altunören O, Güngör Ö. Bleeding after the use of enoxaparin in kidney patients: Case reports and review of the literature. Turk J Nephrol. 2021; 30(4): 318-321.